Cingulate Inc. Warrants
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for th… Read more
Cingulate Inc. Warrants (CINGW) - Net Assets
Latest net assets as of September 2025: $3.47 Million USD
Based on the latest financial reports, Cingulate Inc. Warrants (CINGW) has net assets worth $3.47 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.52 Million) and total liabilities ($7.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.47 Million |
| % of Total Assets | 33.02% |
| Annual Growth Rate | 64.63% |
| 5-Year Change | 476.86% |
| 10-Year Change | N/A |
| Growth Volatility | 704.3 |
Cingulate Inc. Warrants - Net Assets Trend (2019–2024)
This chart illustrates how Cingulate Inc. Warrants's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cingulate Inc. Warrants (2019–2024)
The table below shows the annual net assets of Cingulate Inc. Warrants from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.46 Million | +208.53% |
| 2023-12-31 | $-6.87 Million | -276.95% |
| 2022-12-31 | $3.88 Million | -81.38% |
| 2021-12-31 | $20.84 Million | +1512.73% |
| 2020-12-31 | $1.29 Million | +109.85% |
| 2019-12-31 | $615.88K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cingulate Inc. Warrants's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10848918000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $340.00 | 0.00% |
| Other Components | $115.94 Million | 1555.15% |
| Total Equity | $7.46 Million | 100.00% |
Cingulate Inc. Warrants Competitors by Market Cap
The table below lists competitors of Cingulate Inc. Warrants ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
New Momentum Corporation
PINK:NNAX
|
$330.34K |
|
Grapefruit USA Inc
PINK:GPFT
|
$330.36K |
|
Chapters Group AG
XETRA:CHG
|
$330.40K |
|
Polymeric Resources Corporation
PINK:PLYR
|
$330.61K |
|
Lanbay Inc
PINK:LNBY
|
$330.16K |
|
Syros Pharmaceuticals Inc
NASDAQ:SYRS
|
$329.84K |
|
Fila Korea Ltd.
KQ:081660
|
$329.82K |
|
2G ENERGY - Dusseldorf Stock Exchang
DU:2GB
|
$329.66K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cingulate Inc. Warrants's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -6,869,429 to 7,455,505, a change of 14,324,934.
- Net loss of 15,545,737 reduced equity.
- New share issuances of 25,875,168 increased equity.
- Other factors increased equity by 3,995,503.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-15.55 Million | -208.51% |
| Share Issuances | $25.88 Million | +347.06% |
| Other Changes | $4.00 Million | +53.59% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Cingulate Inc. Warrants's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.44 | $0.05 | x |
| 2020-12-31 | $0.91 | $0.05 | x |
| 2021-12-31 | $14.74 | $0.05 | x |
| 2022-12-31 | $2.75 | $0.05 | x |
| 2023-12-31 | $-3.04 | $0.05 | x |
| 2024-12-31 | $1.96 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cingulate Inc. Warrants utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -208.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.99x
- Recent ROE (-208.51%) is above the historical average (-533.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -1874.76% | 0.00% | 0.00x | 8.57x | $-11.61 Million |
| 2020 | -555.82% | 0.00% | 0.00x | 4.48x | $-7.31 Million |
| 2021 | -99.51% | 0.00% | 0.00x | 1.10x | $-22.82 Million |
| 2022 | -459.82% | 0.00% | 0.00x | 2.94x | $-18.24 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.85 Million |
| 2024 | -208.51% | 0.00% | 0.00x | 1.99x | $-16.29 Million |
Industry Comparison
This section compares Cingulate Inc. Warrants's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cingulate Inc. Warrants (CINGW) | $3.47 Million | -1874.76% | 2.03x | $330.18K |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |